Improving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity

dc.contributor.authorValencia Mahón, Jaris
dc.contributor.authorYáñez, Rosa
dc.contributor.authorMuntión, Sandra
dc.contributor.authorFernández García, María
dc.contributor.authorMartín Rufino, Jorge Diego
dc.contributor.authorZapata González, Agustín Gregorio
dc.contributor.authorBueren, Juan A.
dc.contributor.authorVicente López, María Ángeles
dc.contributor.authorSánchez Guijo, Fermin
dc.date.accessioned2026-02-26T10:34:01Z
dc.date.available2026-02-26T10:34:01Z
dc.date.issued2025-02-17
dc.descriptionTerCel” (Groups: 0002, 0011,0015) I+D+I 2013-2016 Spanish National Plan Plan de Recuperación, Transformación y Resilencia
dc.description.abstractIntroduction: MSCs exhibit regenerative, anti-inflammatory and immunomodulatory properties due to the large amount of cytokines, chemokines and growth factors they secrete. MSCs have been extensively evaluated in clinical trials, however, in some cases their therapeutic effects are variable. Therefore, strategies to improve their therapeutic potential, such as preconditioning with proinflammatory factors, have been proposed. Several priming approaches have provided non-conclusive results, and the duration of priming effects on MSC properties or their response to a second inflammatory stimulus have not been fully addressed.Methods: We have investigated the impact of triple cytokine priming in MSCs on their characterization and viability, their transcriptomic profile, the functionality of innate and acquired immune cells, as well as the maintenance of the response to priming over time, their subsequent responsiveness to a second inflammatory stimulus.Results: Priming MSCs with proinflammatory cytokines (CK-MSCs) do not modify the differentiation capacity of MSCs, nor their immunophenotype and viability. Moreover, cytokine priming enhances the anti-inflammatory and immunomodulatory properties of MSCs against NK and dendritic cells, while maintaining the same T cell immunomodulatory capacity as unstimulated MSCs. Thus, they decrease T-lymphocytes and NK cell proliferation, inhibit the differentiation and allostimulatory capacity of dendritic cells and promote the differentiation of monocytes with an immunosuppressive profile. In addition, we have shown for the first time that proinflammatory priming reduces the variability between different donors and MSC origins. Finally, the effect on CK-MSC is maintained over time and even after a secondary inflammatory stimulus.Conclusions: Cytokine-priming improves the therapeutic potential of MSCs and reduces inter-donor variability.
dc.description.departmentDepto. de Biología Celular
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Ciencia e Innovación (España)
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipUnión Europea
dc.description.sponsorshipJunta de Castilla y León
dc.description.sponsorshipGobierno de Castilla y León
dc.description.statuspub
dc.identifier.citationValencia J, Yáñez RM, Muntión S, Fernández-García M, Martín-Rufino JD, Zapata AG, Bueren JA, Vicente Á, Sánchez-Guijo F. Improving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity. Front Immunol. 2025 Feb 17;16:1473788. doi: 10.3389/fimmu.2025.1473788. PMID: 40034706; PMCID: PMC11872697. Copy Download .nbib Fo
dc.identifier.doi10.3389/fimmu.2025.1473788
dc.identifier.issn1664-3224
dc.identifier.officialurlhttps://doi.org/10.3389/fimmu.2025.1473788
dc.identifier.relatedurlhttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1473788/full
dc.identifier.urihttps://hdl.handle.net/20.500.14352/133330
dc.journal.titleFrontiers in Immunology
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.projectIDRD16/0011
dc.relation.projectIDRD21/0017
dc.relation.projectIDPID2021-123068OB-I00/AEI/10.13039/501100011033
dc.relation.projectIDPI16/01407
dc.relation.projectIDPI18-01379
dc.relation.projectIDGRS1621/A/17
dc.relation.projectIDCAS079P17
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu612.017
dc.subject.ucmCiencias Biomédicas
dc.subject.ucmBiología celular (Biología)
dc.subject.ucmMedicina
dc.subject.unesco2412 Inmunología
dc.subject.unesco2407 Biología Celular
dc.titleImproving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number16
dspace.entity.typePublication
relation.isAuthorOfPublicationbb4cf900-7e50-4af7-b931-82e3773a2be9
relation.isAuthorOfPublication8f748fcd-6b47-4cbc-9045-e8655a12e7aa
relation.isAuthorOfPublication9914b48f-3f93-4a23-aa4a-57fd6d397272
relation.isAuthorOfPublication.latestForDiscovery9914b48f-3f93-4a23-aa4a-57fd6d397272

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Improving the therapeutic profile of MSCs.pdf
Size:
5.58 MB
Format:
Adobe Portable Document Format

Collections